Device for Enrichment of Skeletal Stem Cells for Orthopaedic Applications

随着人口老龄化的增加，迫切需要能够简单修复和增加由于创伤或疾病或衰老而丢失的骨组织的策略，因此，开发能够简单富集来自患者骨髓的骨骼干细胞用于骨科应用的装置的能力是未满足的和迫切需要的临床目标。本项目拟推进Smith and Nephew开发的独特专利细胞分离技术的开发，使其成为临床有效且商业上可行的手术器械。对骨科应用的影响是巨大的，并有可能改善日益老龄化人口的生活质量显着。这种新技术有可能通过增加富集自体骨髓的可及性来改变骨科临床实践。南安普顿小组包括临床医生和基础科学家，他们将使用人类骨髓样本对该设备进行评估，并通过实验研究帮助评估，如果必要的话，还将进一步开发细胞分离设备。该设备富集骨骼干细胞的能力将通过一系列检测以及南安普顿内可用的独特骨形成模型进行评估。学术界、工业界和临床研究人员之间的合作将使细胞富集设备的快速发展成为可能，关键是，用人体组织进行评估，包括临床前研究。这将使我们能够在2年的时间范围内，在南安普顿为S&N的工作计划做出重大贡献，以生成允许申报器械临床使用所需的监管数据。

With an increasing ageing population, strategies that allow the simple repair and augmentation of bone tissue, lost as a consequence of trauma or disease or with ageing, are urgently needed.The ability to develop a device that would allow the simple enrichment of skeletal stem cells from the bone marrow of a patient for orthopaedic application is thus an unmet and urgently required clinical target. This project proposes to progress the development of a unique and patented cell separation technology, developed by Smith and Nephew into a clinically effective and commercially viable surgical device. The implications for orthopaedic use are immense and potential for improving the quality of life in an increasing ageing population significant.This novel technology has the potential to transform orthopaedic clinical practice by increasing the accessibility of enriched autologous marrow. The Southampton group, includes clinicians and basic scientists, that will evaluate the device using human bone marrow samples and, through experimental studies aid in the evaluation and, if necessary, additional development of the cell separation device. The ability of the device to enrich for skeletal stem cells will be assessed by a battery of assays as well as unique models of bone formation available within Southampton.The collaboration between academic, industrial and clinical researchers will allow rapid development of the cell enrichment device and, critically, evaluation with human tissue to include pre-clinical study. This will allow us, within a 2 year time frame, to significantly contribute in Southampton to the programme of work from S&N to the generation of the regulatory data needed to allow clinical use of the proposed device.